Aberdeen Group plc Sells 52,247 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Aberdeen Group plc reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 151,503 shares of the biopharmaceutical company’s stock after selling 52,247 shares during the quarter. Aberdeen Group plc owned about 0.14% of Regeneron Pharmaceuticals worth $85,186,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in REGN. Cidel Asset Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 23.2% during the 3rd quarter. Cidel Asset Management Inc. now owns 568 shares of the biopharmaceutical company’s stock valued at $319,000 after purchasing an additional 107 shares during the last quarter. MidWestOne Financial Group Inc. boosted its stake in Regeneron Pharmaceuticals by 182.0% during the third quarter. MidWestOne Financial Group Inc. now owns 1,097 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 708 shares during the period. DDD Partners LLC increased its position in Regeneron Pharmaceuticals by 4.2% during the third quarter. DDD Partners LLC now owns 21,361 shares of the biopharmaceutical company’s stock valued at $12,011,000 after acquiring an additional 865 shares during the last quarter. WJ Financial Advisors LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at $583,000. Finally, Columbia Bank raised its stake in shares of Regeneron Pharmaceuticals by 3.4% in the third quarter. Columbia Bank now owns 2,219 shares of the biopharmaceutical company’s stock valued at $1,279,000 after acquiring an additional 74 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,636 shares of company stock valued at $2,862,920. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.5%

REGN opened at $803.17 on Monday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock’s fifty day moving average is $762.17 and its two-hundred day moving average is $666.58. The company has a market capitalization of $84.91 billion, a P/E ratio of 19.33, a PEG ratio of 2.16 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $12.07 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be issued a $0.94 dividend. The ex-dividend date is Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.47%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Scotiabank lifted their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Oppenheimer reissued an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Finally, Wells Fargo & Company boosted their price objective on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.